CAJ | 학술논문

目的：观察长春瑞滨联合卡培他滨治疗晚期乳腺癌患者的疗效和不良反应。方法：长春瑞滨25mg/m2，第1、第8天静滴；卡培他滨2.0g/（m2·d），第1～第14天早晚各1次，餐后30min口服。21d为1个周期，最多接受8个周期化疗或至疾病进展。结果：46例患者共完成225个化疗周期，中位化疗5个周期。其中完全缓解（CR）2例，部分缓解（PR）17例，稳定（SD）17例，进展（PD）10例。总有效率（CR+PR）为41.3%，疾病控制率（DCR）为78.3%，中位无进展生存期（TTP）为8.3个月，1、3年生存率分别为70.6%、27.6%。不良反应主要为血液学毒性、手足综合征及静脉炎，未发生治疗相关性死亡。结论：长春瑞滨联合卡培他滨方案是治疗晚期乳腺癌的有效方案，不良反应可以耐受。
목적：관찰장춘서빈연합잡배타빈치료만기유선암환자적료효화불량반응。방법：장춘서빈25mg/m2，제1、제8천정적；잡배타빈2.0g/（m2·d），제1～제14천조만각1차，찬후30min구복。21d위1개주기，최다접수8개주기화료혹지질병진전。결과：46례환자공완성225개화료주기，중위화료5개주기。기중완전완해（CR）2례，부분완해（PR）17례，은정（SD）17례，진전（PD）10례。총유효솔（CR+PR）위41.3%，질병공제솔（DCR）위78.3%，중위무진전생존기（TTP）위8.3개월，1、3년생존솔분별위70.6%、27.6%。불량반응주요위혈액학독성、수족종합정급정맥염，미발생치료상관성사망。결론：장춘서빈연합잡배타빈방안시치료만기유선암적유효방안，불량반응가이내수。
Objective: To explore the clinical efifcacy and tolerability of vinorelbine with xeloda for pa-tients with advanced breast cancer.Methods: Forty-six patients with advanced breast cancer were enrolled in the study. All patients were given 25 mg/m2 of vinorelbine on days 1 and 8, combined with 2.0 g/m2 of xeloda daily from day 1 to 14. The combined chemotherapy was repeated every 21 days as one cycle. Patients received a maximum chemotherapy of 8 cycles or until disease progression.Results: All the 46 patients completed 225 che-motherapy cycles with a 5-cycle median. Adverse events and clinical efifcacy were evaluated on all 46 patients. Complete remission (CR) in 2 patients, partial remission (PR) in 17 patients, stable disease (SD) in 17 patients, and progression of disease (PD) in 10 patients. The overall response rate (CR+PR) was 41.3%, and the disease control rates (DCR) was 78.3%. The median time to progression (TTP) was 8.3 months, 1 year and three-year survival rates were 70.6% and 27.6%.The most commonly observed adverse events were hematologic toxicity and hand-foot syndrome and angeitis. No mortality occurred during the treatment.Conclusion: Vinorelbine com-bined with xeloda is an effective and safe chemotherapeutic regimen for advanced breast cancer, and the adverse reactions are well tolerated.